{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:49Z","timestamp":1788316849493,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["UM1TR004528"],"award-info":[{"award-number":["UM1TR004528"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.amjmed.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:22:34Z","timestamp":1755037354000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sodium Glucose Co-Transporter-2 inhibitors in patients with systemic sclerosis with or without heart failure"],"prefix":"10.1016","volume":"139","author":[{"given":"Silvio Nunes","family":"Augusto Jr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-735X","authenticated-orcid":false,"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2025.08.009_bib0001","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/clc.23508","article-title":"The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now","volume":"43","author":"Johansen","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101305","article-title":"Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs","volume":"48","author":"Alkabbani","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0003","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0004","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A Synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"145","key":"10.1016\/j.amjmed.2025.08.009_bib0005","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"2022","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0006","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ejhf.2286","article-title":"Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors","volume":"23","author":"Herrington","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2025.08.009_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/dom.15171","article-title":"Improving heart failure outcomes with sodium-glucose cotransporter 2 inhibitors in different patient groups","volume":"25","author":"Jhund","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0008","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2337\/dc23-1129","article-title":"Association of continued use of SGLT2 inhibitors from the ambulatory to inpatient setting with hospital outcomes in patients with diabetes: a nationwide cohort study","volume":"47","author":"Singh","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2019.11.013","article-title":"Differential associations of chronic inflammatory diseases with incident heart failure","volume":"8","author":"Prasada","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0010","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/acr.25016","article-title":"Association of systemic sclerosis with incident clinically evident heart failure","volume":"75","author":"Lin","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0011","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1093\/rheumatology\/keac072","article-title":"Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis","volume":"61","author":"Sun","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013405","article-title":"Cardiovascular manifestations of systemic sclerosis: a Danish Nationwide Cohort Study","volume":"8","author":"Butt","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0013","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/s41598-024-57275-9","article-title":"Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023009","article-title":"Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies","volume":"99","author":"Cen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0015","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/rheumatology\/kead599","article-title":"Heart and systemic sclerosis-findings from a national cohort study","volume":"63","author":"Gu\u00e9don","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036730","article-title":"Evaluation of systemic sclerosis primary heart involvement and chronic heart failure in the European Scleroderma Trials and Research Cohort","volume":"14","author":"Gy\u00f6rfi","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0017","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/rheumatology\/kez658","article-title":"Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis","volume":"59","author":"De Luca","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0018","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"Bmj"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2025.08.009_bib0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/medicina61020202","article-title":"Update on the efficacy and safety of Sodium-Glucose Co-Transporter 2 inhibitors in patients with chronic diseases: a systematic review and meta-analysis","volume":"61","author":"Liang","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0021","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.986186","article-title":"Cardiovascular and renal outcomes with Sodium Glucose Co-Transporter 2 inhibitors in patients with type 2 diabetes mellitus: a system review and network meta-analysis","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond Tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.amjmed.2025.08.009_bib0026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of Sodium-Glucose Cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325005297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325005297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:59:26Z","timestamp":1779857966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325005297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0002934325005297"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.08.009","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Co-Transporter-2 inhibitors in patients with systemic sclerosis with or without heart failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}